| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
119,140,000 |
| Market
Cap: |
669.57(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.51 - $6.87 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.9 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Wave Life Sciences is a genetic medicines company. Co.'s primary clinical development programs are designed to treat genetic diseases within the central nervous system, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), and muscular dystrophies, including Duchenne muscular dystrophy (DMD). These programs include: WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD; WVE-003 (silencing), its mutant huntingtin single nucleotide polymorphism 3 molecule for the treatment of HD; and WVE-N531 (splicing), its exon 53 molecule for the treatment of DMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
5,300,000 |
5,300,000 |
14,780,052 |
| Total Buy Value |
$0 |
$26,500,000 |
$26,500,000 |
$46,882,112 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
4 |
| Total Shares Sold |
15,630 |
15,630 |
52,692 |
112,328 |
| Total Sell Value |
$96,421 |
$96,421 |
$272,540 |
$513,264 |
| Total People Sold |
1 |
1 |
1 |
4 |
| Total Sell Transactions |
1 |
1 |
2 |
6 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vargeese Chandra |
Chief Technology Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
88,557 |
|
- |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
71,584 |
|
- |
|
| Moran Kyle |
Chief Financial OfficerOfficer |
• – – |
2020-12-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,084 |
|
-31% |
|
| Bolno Paul |
President and CEO |
• • – |
2020-09-15 |
4 |
AS |
$15.00 |
$1,500,000 |
D/D |
(100,000) |
272,181 |
|
-39% |
|
| Bolno Paul |
President and CEO |
• • – |
2020-09-15 |
4 |
OE |
$2.48 |
$248,000 |
D/D |
100,000 |
372,181 |
|
- |
|
| Bolno Paul |
President and CEO |
• • – |
2020-08-25 |
4 |
AS |
$12.00 |
$300,000 |
D/D |
(25,000) |
272,181 |
|
-23% |
|
| Bolno Paul |
President and CEO |
• • – |
2020-08-25 |
4 |
OE |
$2.48 |
$62,000 |
D/D |
25,000 |
297,181 |
|
- |
|
| Bolno Paul |
President and CEO |
• • – |
2020-07-02 |
4 |
AS |
$10.26 |
$1,520,276 |
D/D |
(147,577) |
272,181 |
|
-20% |
|
| Bolno Paul |
President and CEO |
• • – |
2020-07-02 |
4 |
OE |
$2.48 |
$248,000 |
D/D |
100,000 |
372,181 |
|
- |
|
| Francis Chris |
See Remarks |
• – – |
2020-02-18 |
4 |
AS |
$7.85 |
$21,258 |
D/D |
(2,708) |
31,160 |
|
32% |
|
| Panzara Michael A. |
Chief Medical Officer |
• – – |
2020-02-18 |
4 |
AS |
$7.85 |
$23,401 |
D/D |
(2,981) |
39,349 |
|
32% |
|
| Bolno Paul |
President and CEO |
• • – |
2020-02-18 |
4 |
AS |
$7.85 |
$89,890 |
D/D |
(11,451) |
319,758 |
|
32% |
|
| Vargeese Chandra |
Senior VP, Drug Discovery |
• – – |
2020-02-18 |
4 |
AS |
$7.85 |
$25,026 |
D/D |
(3,188) |
37,057 |
|
32% |
|
| Gaiero David G |
Interim CFO |
• – – |
2020-02-03 |
4 |
AS |
$7.00 |
$4,557 |
D/D |
(651) |
6,392 |
|
36% |
|
| Gaiero David G |
Interim CFOOfficer |
• – – |
2020-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,043 |
|
22% |
|
| Vargeese Chandra |
Senior VP, Drug Discovery |
• – – |
2019-12-03 |
4 |
AS |
$35.00 |
$210,000 |
D/D |
(6,000) |
40,245 |
|
- |
|
| Vargeese Chandra |
Senior VP, Drug Discovery |
• – – |
2019-12-03 |
4 |
OE |
$2.48 |
$14,880 |
D/D |
6,000 |
46,245 |
|
- |
|
| Verdine Gregory L. |
Director |
– • – |
2019-11-20 |
4 |
S |
$30.27 |
$920,213 |
D/D |
(30,039) |
30,000 |
|
- |
|
| Baldry Mark |
Chief Commerical Officer |
• – – |
2019-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
39,000 |
|
- |
|
| Panzara Michael A. |
Chief Medical Officer |
• – – |
2019-07-05 |
4 |
AS |
$26.88 |
$82,368 |
D/D |
(3,058) |
42,330 |
|
- |
|
| Bolno Paul |
President and CEO |
• • – |
2019-03-15 |
4 |
AS |
$45.22 |
$2,273,804 |
D/D |
(50,000) |
331,209 |
|
- |
|
| Bolno Paul |
President and CEO |
• • – |
2019-03-15 |
4 |
OE |
$2.48 |
$124,000 |
D/D |
50,000 |
381,209 |
|
- |
|
| Panzara Michael A. |
Franchise Lead, Neurology |
• – – |
2019-03-11 |
4 |
AS |
$48.00 |
$336,000 |
D/D |
(7,000) |
45,388 |
|
- |
|
| Francis Chris |
See Remarks |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
13,500 |
33,868 |
|
- |
|
| Panzara Michael A. |
Franchise Lead, Neurology |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
52,388 |
|
- |
|
130 Records found
|
|
Page 2 of 6 |
|
|
0.14 (2.43%) 
